Full Press Release Details
ASTRAZENECA LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES AstraZeneca Is First Licensee of Novel VelocImmu ne Technology License Fees Total up to $120 Million Over Six Years.
REGN
ASTRAZENECA LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES AstraZeneca Is First Licensee of Novel VelocImmu ne Technology License Fees Total up to $120 Million Over Six Years
Key Takeaway: ASTRAZENECA LICENSES REGENERON’S VELOCIMMUNE TECHNOLOGY FOR DISCOVERING HUMAN MONOCLONAL ANTIBODIES AstraZeneca Is First Licensee of Novel VelocImmu ne Technology License Fees Total up to $120 Million Over Six Years